Camber Launches Voriconazole for Injection
Camber is excited to welcome Voriconazole for Injection [vor-i-KON-a-zole] to its expanding portfolio.
Voriconazole for Injection is indicated for a variety of fungal infections in adult and pediatric patients (2 years of age and older) including:
- Invasive Aspergillosis
- Candidemia in Non-neutropenic Patients and Other Deep Tissue Candida Infections
- Esophageal Candidiasis
It is also indicated for patients who are intolerant of, or refractory to, other therapy for:
- Scedosporiosis
- Fusariosis
For complete indications, please click here.
Voriconazole for Injection is available in 200 mg Single-Dose Vials.
To learn more about this product, visit: www.camberpharma.com/voriconazole
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






